201 related articles for article (PubMed ID: 18586313)
1. The epidemiology of CA-125 in women without evidence of ovarian cancer in the Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial.
Johnson CC; Kessel B; Riley TL; Ragard LR; Williams CR; Xu JL; Buys SS;
Gynecol Oncol; 2008 Sep; 110(3):383-9. PubMed ID: 18586313
[TBL] [Abstract][Full Text] [Related]
2. Abnormal CA-125 levels in menopausal women without ovarian cancer.
Terada KY; Elia J; Kim R; Carney M; Ahn HJ
Gynecol Oncol; 2014 Oct; 135(1):34-7. PubMed ID: 25127988
[TBL] [Abstract][Full Text] [Related]
3. Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial.
Buys SS; Partridge E; Black A; Johnson CC; Lamerato L; Isaacs C; Reding DJ; Greenlee RT; Yokochi LA; Kessel B; Crawford ED; Church TR; Andriole GL; Weissfeld JL; Fouad MN; Chia D; O'Brien B; Ragard LR; Clapp JD; Rathmell JM; Riley TL; Hartge P; Pinsky PF; Zhu CS; Izmirlian G; Kramer BS; Miller AB; Xu JL; Prorok PC; Gohagan JK; Berg CD;
JAMA; 2011 Jun; 305(22):2295-303. PubMed ID: 21642681
[TBL] [Abstract][Full Text] [Related]
4. Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial.
Buys SS; Partridge E; Greene MH; Prorok PC; Reding D; Riley TL; Hartge P; Fagerstrom RM; Ragard LR; Chia D; Izmirlian G; Fouad M; Johnson CC; Gohagan JK;
Am J Obstet Gynecol; 2005 Nov; 193(5):1630-9. PubMed ID: 16260202
[TBL] [Abstract][Full Text] [Related]
5. Pathologic findings following false-positive screening tests for ovarian cancer in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
Nyante SJ; Black A; Kreimer AR; Duggan MA; Carreon JD; Kessel B; Buys SS; Ragard LR; Johnson KA; Dunn BK; Lamerato L; Commins JM; Berg CD; Sherman ME
Gynecol Oncol; 2011 Mar; 120(3):474-9. PubMed ID: 21144559
[TBL] [Abstract][Full Text] [Related]
6. Proteomic biomarkers in combination with CA 125 for detection of epithelial ovarian cancer using prediagnostic serum samples from the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial.
Moore LE; Pfeiffer RM; Zhang Z; Lu KH; Fung ET; Bast RC
Cancer; 2012 Jan; 118(1):91-100. PubMed ID: 21717433
[TBL] [Abstract][Full Text] [Related]
7. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
[TBL] [Abstract][Full Text] [Related]
8. Extended mortality results for ovarian cancer screening in the PLCO trial with median 15years follow-up.
Pinsky PF; Yu K; Kramer BS; Black A; Buys SS; Partridge E; Gohagan J; Berg CD; Prorok PC
Gynecol Oncol; 2016 Nov; 143(2):270-275. PubMed ID: 27615399
[TBL] [Abstract][Full Text] [Related]
9. Assessing the risk of ovarian malignancy in asymptomatic women with abnormal CA 125 and transvaginal ultrasound scans in the prostate, lung, colorectal, and ovarian screening trial.
Partridge EE; Greenlee RT; Riley TL; Commins J; Ragard L; Xu JL; Buys SS; Prorok PC; Fouad MN
Obstet Gynecol; 2013 Jan; 121(1):25-31. PubMed ID: 23262924
[TBL] [Abstract][Full Text] [Related]
10. Significance of the tumour markers CA 125 II, CA 72-4, CASA and CYFRA 21-1 in ovarian carcinoma.
Hasholzner U; Baumgartner L; Stieber P; Meier W; Hofmann K; Fateh-Moghadam A
Anticancer Res; 1994; 14(6B):2743-6. PubMed ID: 7532929
[TBL] [Abstract][Full Text] [Related]
11. Enrollment of racial and ethnic minorities in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
Pinsky PF; Ford M; Gamito E; Higgins D; Jenkins V; Lamerato L; Tenorio S; Marcus PM; Gohagan JK
J Natl Med Assoc; 2008 Mar; 100(3):291-8. PubMed ID: 18390022
[TBL] [Abstract][Full Text] [Related]
12. Prevalence of ovarian cancer among women with a CA125 level of 35 U/ml or less.
Kobayashi H; Yamada Y; Sado T; Sakata M; Yoshida S; Kawaguchi R; Kanayama S; Shigetomi H; Haruta S; Tsuji Y; Ueda S; Kitanaka T; Oi H
Gynecol Obstet Invest; 2008; 65(2):133-8. PubMed ID: 17957102
[TBL] [Abstract][Full Text] [Related]
13. Potential effect of the risk of ovarian cancer algorithm (ROCA) on the mortality outcome of the Prostate, Lung, Colorectal and Ovarian (PLCO) trial.
Pinsky PF; Zhu C; Skates SJ; Black A; Partridge E; Buys SS; Berg CD
Int J Cancer; 2013 May; 132(9):2127-33. PubMed ID: 23065684
[TBL] [Abstract][Full Text] [Related]
14. Outcomes from ovarian cancer screening in the PLCO trial: Histologic heterogeneity impacts detection, overdiagnosis and survival.
Temkin SM; Miller EA; Samimi G; Berg CD; Pinsky P; Minasian L
Eur J Cancer; 2017 Dec; 87():182-188. PubMed ID: 29156299
[TBL] [Abstract][Full Text] [Related]
15. Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation.
Menon U; Talaat A; Jeyarajah AR; Rosenthal AN; MacDonald ND; Skates SJ; Sibley K; Oram DH; Jacobs IJ
Br J Cancer; 1999 Jul; 80(10):1644-7. PubMed ID: 10408412
[TBL] [Abstract][Full Text] [Related]
16. Large prospective study of ovarian cancer screening in high-risk women: CA125 cut-point defined by menopausal status.
Skates SJ; Mai P; Horick NK; Piedmonte M; Drescher CW; Isaacs C; Armstrong DK; Buys SS; Rodriguez GC; Horowitz IR; Berchuck A; Daly MB; Domchek S; Cohn DE; Van Le L; Schorge JO; Newland W; Davidson SA; Barnes M; Brewster W; Azodi M; Nerenstone S; Kauff ND; Fabian CJ; Sluss PM; Nayfield SG; Kasten CH; Finkelstein DM; Greene MH; Lu K
Cancer Prev Res (Phila); 2011 Sep; 4(9):1401-8. PubMed ID: 21893500
[TBL] [Abstract][Full Text] [Related]
17. Development and validation of circulating CA125 prediction models in postmenopausal women.
Sasamoto N; Babic A; Rosner BA; Fortner RT; Vitonis AF; Yamamoto H; Fichorova RN; Titus LJ; Tjønneland A; Hansen L; Kvaskoff M; Fournier A; Mancini FR; Boeing H; Trichopoulou A; Peppa E; Karakatsani A; Palli D; Grioni S; Mattiello A; Tumino R; Fiano V; Onland-Moret NC; Weiderpass E; Gram IT; Quirós JR; Lujan-Barroso L; Sánchez MJ; Colorado-Yohar S; Barricarte A; Amiano P; Idahl A; Lundin E; Sartor H; Khaw KT; Key TJ; Muller D; Riboli E; Gunter M; Dossus L; Trabert B; Wentzensen N; Kaaks R; Cramer DW; Tworoger SS; Terry KL
J Ovarian Res; 2019 Nov; 12(1):116. PubMed ID: 31771659
[TBL] [Abstract][Full Text] [Related]
18. Cancer screening and risk-reducing behaviors of women seeking genetic cancer risk assessment for breast and ovarian cancers.
MacDonald DJ; Sarna L; Uman GC; Grant M; Weitzel JN
Oncol Nurs Forum; 2006 Nov; 33(2):E27-35. PubMed ID: 16518435
[TBL] [Abstract][Full Text] [Related]
19. Results from an ultrasound-based familial ovarian cancer screening clinic: a 10-year observational study.
Tailor A; Bourne TH; Campbell S; Okokon E; Dew T; Collins WP
Ultrasound Obstet Gynecol; 2003 Apr; 21(4):378-85. PubMed ID: 12704748
[TBL] [Abstract][Full Text] [Related]
20. Ovarian cancer screening in women with a family history of breast or ovarian cancer.
Lacey JV; Greene MH; Buys SS; Reding D; Riley TL; Berg CD; Fagerstrom RM; Hartge P
Obstet Gynecol; 2006 Nov; 108(5):1176-84. PubMed ID: 17077240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]